US regulatory status: approved. Molecular target: Dopamine receptors; D2 & D3.
- Target
- Dopamine receptors; D2 & D3
- Mechanism
- Serotonin (5-HT) receptor antagonist
pharma · Hypoparathyroidism · Postbariatric Hypoglycemia · MBX
MBX Biosciences
MBX Biosciences drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Carmel, USA HQ
2019 Founded
74 Employees
Public company Type
MBX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Carmel, USA
- Founded
- 2019
- Employees
- 74
- Programs
- 7
- Drugs
- 3
- Patents
- 0
MBX Biosciences pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
MBX Biosciences drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to MBX Biosciences in public FDA and regional records.
-
Development asset linked to MBX Biosciences in public FDA and regional records.